In this study, we aimed to categorically investigate and quantify PD-L1 immunoreactivity in three major sarcoma subtypes; chondrosarcoma (CS), liposarcoma (LS) and undifferentiated pleomorphic sarcoma (UPS), using the SP142 and SP263 assays, which are two of the most used in vitro diagnostic regulation (IVDR)-approved PD-L1 immunohistochemistry assays used in clinical settings. This evidence concerns the gene CD274 and liposarcoma.